Nami Therapeutics Corp.

Storrs, CT · Biotech · Private

Holmium-166-containing mesoporous silica nanoparticles for intraperitoneal radionuclide therapy of ovarian cancer

Grants
$3.2M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases$224,946
Federal grantDepartment of Health and Human Services · Phase II · Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-radiotherapy for Treatment of Ovarian Cancer Metastases$2,025,186
Federal grantDepartment of Health and Human Services · Phase II · Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-radiotherapy for Treatment of Ovarian Cancer Metastases$971,041
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3119MEDITATI INC.——
3120BIOPICO SYSTEMS Inc.——
3121Appia Bio——
3122Nami Therapeutics Corp.——
3123Silicon Insite, Inc.——
3124OncoSolutions LLC——
3125ASDDR, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.